# US 2025/0152660 A1 · SCO-spondin-derived polypeptides for treating biological barriers dysfunction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152660 A1
- Document ID: US20250152660A1
- Status: Published application
- Kind: A1
- Application number: 18/715,447
- Filed: 2022-12-01
- Published: 2025-05-15
- Earliest claimed: 2021-12-01
- Assignees: Axoltis Pharma
- Applicants: Axoltis Pharma
- Inventors: Sighild Brunhilde Adeline LEMARCHANT; Yann GODFRIN
- Web page: https://patentgrep.com/patent/US20250152660A1

## CPC

- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention concerns polypeptides derived from SCO-spondin for treating a biological barrier dysfunction. More particularly the invention relates to said polypeptides for treating a biological barrier dysfunction in diseases or conditions comprising vascular diseases, infections, immune system hyper-responsiveness, inflammatory diseases or autoimmune diseases, chronic kidney disease, intestinal diseases, macular degeneration, diabetic macular edema, epilepsy, neuropathic pain, CNS diseases and disorders, and aging. The invention also relates to said polypeptides for treating a biological barrier dysfunction in a situation where a disease or condition is absent or not yet diagnosed.

## Claims

### Claim 1

A method for treating a biological barrier dysfunction, or for protecting a biological barrier, in a subject in need thereof, comprising administering to said subject an effective amount of peptide of amino acid sequence
(SEQ ID NO: 1)
X1-W-S-A1-W-S-A2-C-S-A3-A4-C-G-X2
in which:
A1, A2, A3 and A4 consists of amino acid sequences consisting of 1 to 5 amino acids,
X1 and X2 consists of amino acid sequences consisting of 1 to 6 amino acids; or X1 and X2 are absent;
it being possible for the N-terminal amino acid to be acetylated, for the C-terminal amino acid to be amidated, or the N-terminal amino acid to be acetylated and the C-terminal amino acid to be amidated,
wherein said peptide decreases the biological barrier permeability.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biological barrier dysfunction comprises altered tight junctions between adjacent cells forming the endothelial or epithelial layers of a biological barrier; transendothelial and/or transepithelial electrical resistance decrease; deregulation of Claudin-5 expression or distribution; and/or the trans-compartment permeability deregulation of specific compounds or molecules.

### Claim 3 (depends on 1)

The method of claim 1, wherein the biological barrier is the blood-brain barrier, the blood-spinal cord barrier, the inner blood-retina barrier, the blood-cerebrospinal fluid barrier, the lung endothelial barrier, a vascular-parenchyma or a vascular-fluid barrier.

### Claim 4 (depends on 1)

The method of claim 1, wherein the biological barrier dysfunction is one occurring in disease or conditions comprising vascular diseases, infections, immune system hyper-responsiveness, inflammatory diseases or autoimmune diseases, chronic kidney disease, intestinal diseases, macular degeneration, diabetic macular edema, epilepsy, CNS diseases and disorders, and aging.

### Claim 5 (depends on 1)

The method of claim 1, wherein the peptide is of amino acid sequence W-S-A1-W-S-A2-C-S-A3-A4-C-G (SEQ ID NO: 2), in which A1, A2, A3 and A4 consists of amino acid sequences consisting of 1 to 5 amino acids.

### Claim 6 (depends on 1)

The method of claim 1, wherein
A1 is chosen from G, V, S, P and A, preferably G, S,
A2 is chosen from G, V, S, P and A, preferably G, S,
A3 is chosen from R, A and V, preferably R, V, and/or
A4 is chosen from S, T, P and A, preferably S, T.

### Claim 7 (depends on 1)

The method of claim 1, wherein A1 and A2 are independently chosen from G and S, and/or A3-A4 is chosen from R-S or V-S or V-T or R-T.

### Claim 8 (depends on 1)

The method of claim 1, wherein the peptide is of a sequence selected from the group consisting of sequences SEQ ID NO: 3-63.

### Claim 9 (depends on 1)

The method of claim 1, wherein the peptide is a linear peptide or a cyclized peptide wherein the two cysteines appearing on the peptide formula of SEQ ID NO: 1 or 2 form a disulfide bridge.

### Claim 10 (depends on 1)

The method of claim 1, which is the peptide of sequence SEQ ID NO: 3, wherein the peptide is a linear peptide or a cyclized peptide wherein the two cysteines form a disulfide bridge, or a mixture of both.

### Claim 11 (depends on 1)

The method of claim 1, which is the peptide of sequence SEQ ID NO: 3, wherein the peptide is a cyclized peptide wherein the two cysteines form a disulfide bridge.

### Claim 12 (depends on 1)

The method of claim 1, wherein the peptide is for use in a patient who has been determined as having a biological barrier dysfunction, deteriorated tight junctions, abnormal Claudin-5 expression level or distribution, deregulated transendothelial and/or transepithelial electrical resistance at the level of the biological barrier, the trans-compartment permeability deregulation.

### Claim 13 (depends on 6)

The method of claim 6, wherein
A1 is chosen from G,S,
A2 is chosen from G,S,
A3 is chosen from R, V, and/or
A4 is chosen from S,T.
